|
|
Volumn 21, Issue 10 Suppl, 2003, Pages
|
|
Use of CA-125 to assess response to new agents in ovarian cancer trials.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CA 125 ANTIGEN;
NEW DRUG;
BLOOD;
CLINICAL TRIAL;
DISEASE COURSE;
FEMALE;
HUMAN;
IMMUNOLOGY;
METHODOLOGY;
OVARY TUMOR;
PATIENT SELECTION;
RECURRENT DISEASE;
REVIEW;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CA-125 ANTIGEN;
CLINICAL TRIALS;
DISEASE PROGRESSION;
DRUGS, INVESTIGATIONAL;
FEMALE;
HUMANS;
OVARIAN NEOPLASMS;
PATIENT SELECTION;
RECURRENCE;
RESEARCH DESIGN;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 1342314663
PISSN: None
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/jco.2003.01.223 Document Type: Review |
|
Times cited : (208)
|
|
References (25)
|
